Medication Management Follow-Ups: What Happens After the First Visit?
Written by Dr. Oswaldo Romero, PMHNP-BC
So the initial consultation is done. A treatment plan has been discussed, and both patient and provider have agreed to move forward together. Now what?
For many patients, the follow-up visit is where the real work of psychiatric care begins, and it often looks very different from what people expect. Medication management follow-ups are not just quick check-ins to refill a prescription. They are structured, purposeful appointments designed to ensure that treatment is working, that it is safe, and that it is moving in the right direction.
Here is what actually happens, and why it matters.
The First Follow-Up: Checking In Early
After starting a new psychiatric medication, the first follow-up typically happens within two to four weeks. There is a good reason for this timing: most psychiatric medications take at least two to four weeks to begin showing their full therapeutic effects, but side effects can appear much sooner. That early window is critical.
During this visit, the provider is evaluating several things at once:
- Has the medication caused any side effects — and if so, are they tolerable or do they need to be addressed?
- Is there any early sign of improvement, even if subtle?
- Is the patient actually taking the medication as prescribed?
- Are there any safety concerns, including changes in mood, sleep, appetite, or thoughts of self-harm?
Research published in JAMA recommends initial contact at two weeks after starting an antidepressant, with subsequent visits every four to six weeks until remission or a satisfactory treatment response is achieved. The NICE guidelines similarly recommend follow-up at two weeks, then at two-to-four-week intervals during the first three months. Studies show that nearly half of patients who receive an initial antidepressant prescription discontinue treatment during the first month, often because side effects were not addressed or because they did not feel the medication was working yet.
This is why early follow-up is so important. It is the provider's opportunity to say: "What you are experiencing is expected. Let's talk about it. Let's adjust if we need to."
What Gets Measured Gets Better
One of the most important, and often invisible, parts of a medication management follow-up is measurement-based care. This means using validated screening tools, like the PHQ-9 for depression or the GAD-7 for anxiety, at every visit to track symptoms over time.
Why does this matter? Because memory is unreliable, and subjective impressions can be misleading, for both patients and providers. A patient might say, "I think I feel a little better," but a PHQ-9 score that dropped from 18 to 11 tells a much more precise story. Conversely, a patient might feel discouraged because they are still struggling, but the data shows meaningful progress that might otherwise go unrecognized.
The American Psychiatric Association recommends the use of quantitative measures as part of assessment in all psychiatric evaluations. Studies have shown that patients receiving measurement-based care have up to a 75% improvement in remission rates compared to those receiving treatment without routine symptom measurement. Measurement-based care also accelerates recovery — one clinical trial found that the median time to remission was cut in half when structured symptom monitoring was used to guide dose adjustments.
Dose Adjustments: The Art and Science of Getting It Right
Psychiatric medication is rarely a "set it and forget it" situation. Most medications are started at a lower dose and gradually increased — a process called titration. The follow-up visit is where titration decisions are made.
The provider considers several factors:
- Is the current dose producing a meaningful reduction in symptoms?
- Are side effects manageable, or are they interfering with daily life?
- Is there room to increase the dose safely?
- Has enough time passed to fairly evaluate the medication's effect?
This last point is crucial. Patients sometimes feel frustrated when a medication does not seem to work immediately, but most psychiatric medications need adequate time at an adequate dose before their effectiveness can be judged. Absence of any benefit after four weeks of treatment at a recommended dose should prompt consideration of a change in strategy, but not before giving the medication a fair trial.
When a Medication Is Not Working
Sometimes, despite best efforts, a medication does not produce the desired results. This is not a failure, it is a normal part of psychiatric treatment. Research shows that only about one-third of patients achieve remission with their first antidepressant. The good news is that there are well-established next steps.
Options when a medication is not working include:
- Increasing the dose if there is room within the therapeutic range
- Switching to a different medication, either within the same class or to a different class
- Augmenting the current medication by adding a second medication that enhances its effects
- Adding psychotherapy if it is not already part of the treatment plan
- Re-evaluating the diagnosis — sometimes a lack of response is a signal that the original diagnosis needs to be reconsidered
The decision about which path to take is made collaboratively, based on the patient's experience, preferences, and clinical data. This is shared decision-making in action — and it is one of the most important things that happens during a follow-up visit.
The Maintenance Phase: When Things Are Going Well
Once a patient has achieved a good response — symptoms are well-controlled, functioning has improved, and side effects are manageable — the visits do not stop. They shift into what is called the maintenance phase.
During maintenance, follow-up visits may be spaced further apart — every two to three months, or even every three to six months for patients who are stable. But these visits still serve critical purposes:
- Monitoring for late-onset side effects, such as weight gain or metabolic changes
- Ensuring continued adherence to the medication regimen
- Watching for early signs of relapse
- Adjusting the treatment plan as life circumstances change
Guidelines recommend that once symptoms are relieved, pharmacotherapy should be continued for at least six months to prevent relapse. Patients at high risk (those with two or more previous episodes or with depression lasting more than two years) may need to continue treatment for at least two years, and possibly indefinitely.
Medication Adherence: The Elephant in the Room
Here is a reality that providers and patients both need to acknowledge: taking medication consistently is hard. Research shows that approximately 60% of patients with bipolar disorder and a significant proportion of patients with depression and anxiety struggle with medication adherence.
The reasons are varied: side effects, feeling better and thinking the medication is no longer needed, cost, complexity of the regimen, stigma, or simply forgetting. Non-adherence is linked to poorer outcomes, including increased hospitalizations, higher risk of relapse, and even increased risk of suicide.
This is why every follow-up visit includes a conversation about adherence — not as a lecture, but as a collaborative check-in. Strategies that help include:
- Simplifying the medication regimen whenever possible
- Providing clear psychoeducation about why continued treatment matters, even when symptoms improve
- Addressing side effects proactively rather than waiting for the patient to bring them up
- Using motivational interviewing techniques to explore ambivalence about treatment
- Involving family members or support systems when appropriate
The most important factor in adherence? Trust in the provider. Studies consistently show that a strong therapeutic relationship and regular patient-provider communication are among the most powerful predictors of whether a patient stays on their medication.
What Follow-Ups Are Not
It is worth being clear about what medication management follow-ups are not:
- They are not just prescription refills. Every visit involves clinical assessment, symptom measurement, and collaborative decision-making.
- They are not a guarantee that a specific medication will be continued indefinitely. Treatment plans evolve based on clinical response and changing needs.
- They are not a substitute for therapy. Medication management and psychotherapy serve different but complementary roles, and many patients benefit from both.
- They are not emergency or crisis services. R&K Wellness Group is not an emergency or crisis service. Patients experiencing a psychiatric emergency should call 988 (the Suicide and Crisis Lifeline), go to the nearest emergency room, or call 911.
The Bottom Line
Medication management follow-ups are where psychiatric treatment comes to life. They are the visits where data is collected, progress is measured, medications are fine-tuned, and the treatment plan evolves in response to real-world results. They require active participation from both the patient and the provider — and they work best when built on a foundation of honesty, trust, and shared goals.
The first visit may open the door, but it is the follow-ups that walk through it.
References
Management of Depression in Adults: A Review. Simon GE, Moise N, Mohr DC. JAMA. 2024;332(2):141-152. doi:10.1001/jama.2024.5756.
Routine Use of Patient Reported Outcome Measures (PROMs) for Improving Treatment of Common Mental Health Disorders in Adults. Kendrick T, El-Gohary M, Stuart B, et al. The Cochrane Database of Systematic Reviews. 2016;7:CD011119. doi:10.1002/14651858.CD011119.pub2.
Resource Document on Implementation of Measurement-Based Care. Kathryn Ridout, Erik R. Vanderlip, Carol L. Alter, et al. American Psychiatric Association (2023).
Measurement-Based Care to Enhance Antidepressant Treatment Outcomes in Major Depressive Disorder. Husain MI, Nigah Z, Ansari SUH, et al. JAMA Network Open. 2025;8(9):e2529427. doi:10.1001/jamanetworkopen.2025.29427.
Diagnosis and Treatment of Bipolar Disorder: A Review. Nierenberg AA, Agustini B, Köhler-Forsberg O, et al. JAMA. 2023;330(14):1370-1380. doi:10.1001/jama.2023.18588.
Interventions to Improve Medication Adherence in Persons With Mental Disorders. Kedare J, Faye A. Current Opinion in Psychiatry. 2025;38(4):309-315. doi:10.1097/YCO.0000000000000993.
Factors Influencing Adherence to Psychopharmacological Medication - The Doctors' Perspective. Peska M, Artmüller S, Rothenberg M, Winkler D, Pjrek E. Journal of Psychiatric Research. 2025;191:628-633. doi:10.1016/j.jpsychires.2025.09.069.
Managing Depression in Medical Outpatients. Whooley MA, Simon GE. The New England Journal of Medicine. 2000;343(26):1942-50. doi:10.1056/NEJM200012283432607.